FDA declines Grace's stroke drug over manufacturing and packaging issues, shares slump
April 23 (Reuters) - Grace Therapeutics said on Thursday the U.S. Food and Drug Administration declined to approve its drug for a rare type of stroke, citing deficiencies in chemistry, manufacturing and controls and non-clinical data. Shares of the Princeton, New Jersey-based company were down 43%. 
